Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000868 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00000868 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants.
The verdict
NCT00000868, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of giving healthy volunteers a new oral HIV vaccine which has been incorporated into a bacterial cell. This oral vaccine (HIV-1 LAI gp120) will be given with or without a different injected HIV vaccine (HIV-1 MN rgp120). Vaccines are preparations that are introduced into the body to try to prevent infection or create resistance to infection. This study examines a new oral vaccine to see if it can improve the immune system's ability to fight the HIV virus when given alone or with another injected vaccine.
Interventions
- BIOLOGICAL rgp120/HIV-1MN
- BIOLOGICAL MF59
- BIOLOGICAL Aluminum hydroxide
- BIOLOGICAL Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Est. Completion | 2000-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000868
The ClinicalTrials.gov registry entry for NCT00000868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which rgp120/HIV-1MN is the first listed.
NCT00000868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000868 about?
NCT00000868 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers". The purpose of this study is to evaluate the safety and effectiveness of giving healthy volunteers a new oral HIV vaccine which has been incorporated into a bacterial cell. This oral vaccine (HIV-1 LAI gp120) will be given with or without a different injected HIV vaccine (HIV-1 MN rgp120). Vaccines...
What is the current status of trial NCT00000868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. Estimated completion is 2000-05.
What interventions are being tested in trial NCT00000868?
The interventions under investigation include: rgp120/HIV-1MN (BIOLOGICAL), MF59 (BIOLOGICAL), Aluminum hydroxide (BIOLOGICAL), Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000868?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.